Receive The Newest Study Notifications

Rafael Pharmaceuticals Inc.(“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today the launch of Rafael Trial Connect, a web portal available on the Company’s website that will serve as a resource to both...

- Potential to Accelerate Application of T-Cell Therapy to Other Solid Tumors Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced initiation...

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it received input from the U.S. Food and Drug Administration (FDA) on its End-of Phase 2 questions and has...

RegeneRx Biopharmaceuticals, Inc., (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today confirmed that the first patient enrolled in a single-blinded, phase 2 clinical trial...

-- Eagle plans to conduct a Pilot Study shortly followed by a Pivotal Trial -- -- Pivotal Trial expected to be completed within approximately 12 months of commencing enrollment -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today announced a clinical...

 INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported positive preliminary data today during a presentation at Cambridge Healthtech Institute’s 7th Annual...

Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for assessment the Phase 3 protocol for using belapectin (GR-MD-02) for the treatment of compensated non-alcoholic steatohepatitis...

Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis U.S. FDA submission for children planned for 4Q 2019 PARIS and TARRYTOWN, NY – August 6, 2019 – A pivotal Phase 3 trial evaluating...

Provention Bio, Inc. (PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to teplizumab...

Alkahest, Inc., a clinical-stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced top-line data from its phase 2 clinical trial of its candidate GRF6019 in mild-to-moderate Alzheimer’s disease dementia...

- Single topical dose of SQX770 delayed time to next herpes labialis outbreak - Favorable safety and tolerability profile observed with no serious adverse events - Results confirm previous studies including double blind Phase 1 trial data; single topical dose of...

- MRT5005 was generally well tolerated at low and mid-dose levels; no serious adverse events reported at any dose level -- -- Marked increases in ppFEV1 (percent predicted forced expiratory volume in one second) observed after single dose of MRT5005, primarily at...

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that it enrolled the first...

Recent Milestone Demonstrates Continued Progress Across Three Concurrent Studies of VAL-083 in Different Phases of GBM Progression DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel...

On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis in the U.S., Europe, Israel and Canada in 2019 Company to host webcast and conference call on August 7, 2019 at 8:30 am ET to report second quarter 2019...

The EndBrainCancer Initiative (EBCI) urges support for the new  guidelines proposed by the FDA entitled "Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry." With the public...

NIH and partners to assess whether Omalizumab can reduce allergic reactions. Though food allergy affects more than 4.8 million children in the United States, no approved preventative treatments currently exist. While experimental desensitization strategies are...

EMPROVE Trial Shows That, In Patients with Severe Heterogeneous Emphysema, the Spiration Valve System Provides Significant Improvement in Multiple Efficacy Outcomes, with an Acceptable Safety Profile Olympus, a global technology leader in designing and delivering...

First-in-class candidate targets microglia to slow or halt neuroinflammation and disease progression ALZT-OP1 trial being conducted under an SPA with expected completion in late 2020 AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend...

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA)...